Thu, January 12, 2012Wed, January 11, 2012Tue, January 10, 2012Mon, January 9, 2012Sun, January 8, 2012Sat, January 7, 2012Fri, January 6, 2012Thu, January 5, 2012Wed, January 4, 2012Tue, January 3, 2012Mon, January 2, 2012Sat, December 31, 2011Fri, December 30, 2011Thu, December 29, 2011Wed, December 28, 2011Tue, December 27, 2011China Kanghui Holdings Receives FDA Approvals for Hip and Knee Systems
Published in Health and Fitness on Friday, January 6th 2012 at 4:47 GMT by Market Wire
China Kanghui Holdings Receives FDA Approvals for Hip and Knee Systems -- CHANGZHOU, China, Jan. 6, 2012 /PRNewswire-Asia/ --
China Kanghui Holdings Receives FDA Approvals for Hip and Knee Systems
CHANGZHOU, China, Jan. 6, 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: [ KH ]) ("Kanghui" or the "Company"), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced that the Company's wholly-owned subsidiary, TGM Medical, Inc. ("TGM"), has received approvals from the Food and Drug Administration of the United States (the "FDA") for its Helicon™ Hip System ("HHS"), Milestone Knee System ("MKS") and related surgical instruments.
Mr. Libo Yang, Chief Executive Officer of the Company, stated, "We are very pleased that our recent acquisitions not only have laid a strong foundation for our future growth but also provide us with strong momentum for 2012. With successful FDA approvals for TGM's HHS and MKS, we are well-positioned to launch these products this year to kick start our reconstructive joint segment. We have a good start in 2012 and will continue to implement our business opportunities and growth strategies."
About China Kanghui Holdings
Founded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma and spine. It has an extensive network of distributors for its products in China. In addition, Kanghui's products are distributed in 28 countries. Kanghui has strong research and development capabilities, focused on developing new proprietary products, including new product lines, extensions of existing product lines and enhancements of existing products. For more information, please visit [ www.kanghui.com ].
Contact:
China Kanghui Holdings Investor Relations Department
+1-888-321-2558
Asia Bridge Capital Limited
Carene Toh
+86-186 1835 6339
[ carene.toh@asiabridgegroup.com ]
SOURCE China Kanghui Holdings
[ Back to top ] RELATED LINKS
[ http://www.kanghui.com ]
